
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc. is strategically positioned for growth through its innovative TRACER platform, which is anticipated to generate revenues from collaborations progressing toward clinical trials in the 2030s. The company has demonstrated promising preclinical results, such as VY1706's ability to significantly reduce tau messenger RNA and protein levels while ensuring lower liver exposure compared to traditional AAV9 approaches, suggesting enhanced efficacy and safety. Additionally, the recent advancements in non-viral delivery methods indicate a competitive edge in sustaining central nervous system exposure, reinforcing the potential for durable clinical benefits in treating severe neurological diseases.
Bears say
Voyager Therapeutics Inc. has faced significant challenges in advancing its gene therapy programs, leading to concerns about the viability of its pipeline and the potential for long-term profitability. The company's investment in AAV-based therapies has been met with setbacks, highlighting issues related to clinical trial outcomes and the competitive landscape in the gene therapy market. Additionally, financial data indicates rising operational costs and a need for substantial funding, which may dilute existing shareholder value and contribute to a negative perception regarding the stock.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares